The Lancet Commission on hepatocellular carcinoma

https://www.thelancet.com/commissions-do/hepatocellular-carcinoma?dgcid=hubspot_email_infocusalerts-oncology_feature_lancethcc25&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-92GtDAEvtavRJjVSREYsLj9ljK5nwgrLxxbdEzNWUmgWpNKovqtuamnHfHyDNwhhaxsKhTLvYjxaj3DokSF0dQMLwV1Q&_hsmi=376202211&utm_content=375562311&utm_source=hs_email Liver cancer is the sixth most common cancer and the third leading cause of cancer-related mortality globally. The number of new liver cancers will nearly double, from 0·87 million in 2022 to 1·52 million in 2050, if there is no change in the current trend. The Lancet Commission on hepatocellular carcinoma addresses the severity of hepatocellular carcinoma over the next 25 years. The Commission aims to define a goal for reducing the global hepatocellular carcinoma burden and outline ten evidence-based recommendation for actions. These recommendations cover various areas, including awareness campaigns, improvements in health-care delivery, and access to treatment, as well as policy and legislative changes.